You can buy or sell DMPI and other stocks, options, ETFs, and crypto commission-free!
DelMar Pharmaceuticals, Inc. Common Stock, also called DelMar Pharmaceuticals, is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. Read More It offers VAL-083; drug discovery research; as well as patents and intellectual property. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Research And Development
PR NewswireFeb 12
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 12, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the second quarter ended December 31, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on February 19, 2019 at 4:30 p.m. Eastern Time. "During the second quar...
Expected May 15, After Hours